Mizuho raised the firm’s price target on Welltower (WELL) to $141 from $136 and keeps an Outperform rating on the shares. The firm says that despite healthcare real estate investment trusts’ outperformance in fiscal 2024, it continues to like the subsector into fiscal 2025, but feels “some rotation is warranted. Mizuho reiterates a positive stance on senior housing and shifted to neutral from positive on the skilled nursing facility group. It recommends rotating into life sciences as it sees venture funding improving through the year.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WELL:
- Welltower price target raised to $142 from $133 at Scotiabank
- Welltower Inc. Reports Strong Q3 2024 Earnings
- Welltower raises FY24 normalized FFO view to $4.27-$4.33 from $4.13-$4.21
- Welltower reports Q3 normalized FFO $1.11, consensus $1.04
- Welltower options imply 3.4% move in share price post-earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
